Here’s what you should know:
1. Takeda began its squeeze-out July 6, ending it July 26.
2. Takeda acquired a total of 9,532,694 ordinary shares. About 22,500 warrants were tendered into the squeeze-out.
3. Takeda began paying for the securities Aug. 1.
4. TiGenix will no longer be traded on the U.S. Securities and Exchange Commission. The company was delisted from the Nasdaq July 26.
More articles on gastroenterology:
Where ASCs fit in the healthcare landscape: key ideas for success from Pacific Rim Outpatient Surgery Center’s Gary Richberg
How a New York-based ASC is preparing for outcomes based reimbursement
The necessary change for an ASC’s sustainability: key thoughts from South Portland Surgical Center’s Lianna McDowell
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.